VIVUS to Highlight Integrated Approach to More Effective Weight Management in Panel Discussion at the Cleveland Clinic 2019 M...
October 21 2019 - 7:30AM
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical
company, announced today that John Amos, Chief Executive Officer,
will participate in a panel discussion at the Cleveland Clinic 2019
Medical Innovation Summit, which is taking place October 21 – 23 in
Cleveland. The panel discussion, titled “Beneath the Epidemic.
Treating Obesity.” will be held on Tuesday, October 22 at 2:35 PM
ET at Upper Concourse, Room 4.
“The rapidly growing obesity epidemic is
becoming a greater threat to the long term health of the global
population, resulting in lower quality of life, greater medical
challenges and higher out-of-pocket insurance costs,” said John
Amos, Chief Executive Officer of VIVUS. “We believe that VIVUS is
uniquely positioned to play a critical role in providing integrated
solutions that utilize both BMI therapeutics as well as information
solutions. Qsymia is clinically proven to help patients achieve and
maintain a healthy body mass index, and our innovative VIVUS Health
Platform is enabling more patients to access and adhere to
effective treatment. VIVUS is honored and humbled to have the
opportunity to showcase our unique and innovative approach to
addressing the obesity epidemic at a world renowned healthcare
center such as the Cleveland Clinic.”
About Qsymia
Qsymia is approved in the United States and is
indicated as an adjunct to a reduced-calorie diet and increased
physical activity for chronic weight management in adults with an
initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27
kg/m2 or greater (overweight) in the presence of at least one
weight-related medical condition such as high blood pressure, type
2 diabetes, or high cholesterol.
The effect of Qsymia on cardiovascular morbidity
and mortality has not been established. The safety and
effectiveness of Qsymia in combination with other products intended
for weight loss, including prescription and over-the-counter drugs,
and herbal preparations, have not been established.
Important Safety
Information
Qsymia (phentermine and topiramate
extended-release) capsules CIV is contraindicated in pregnancy; in
patients with glaucoma; in hyperthyroidism; in patients receiving
treatment or within 14 days following treatment with monoamine
oxidase inhibitors; or in patients with hypersensitivity to
sympathomimetic amines, topiramate, or any of the inactive
ingredients in Qsymia.
Qsymia can cause fetal harm. Females of
reproductive potential should have a negative pregnancy test before
treatment and monthly thereafter and use effective contraception
consistently during Qsymia therapy. If a patient becomes pregnant
while taking Qsymia, treatment should be discontinued immediately,
and the patient should be informed of the potential hazard to the
fetus.
The most commonly observed side effects in
controlled clinical studies, 5% or greater and at least 1.5 times
placebo, include paraesthesia, dizziness, dysgeusia, insomnia,
constipation, and dry mouth.
About VIVUS
VIVUS is a biopharmaceutical company
committed to the development and commercialization of innovative
therapies that focus on advancing treatments for patients with
serious unmet medical needs. For more information, please
visit www.vivus.com.
Forward-Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995 and are subject to risks,
uncertainties and other factors, including risks and uncertainties
related to our ability to execute on our business strategy to
enhance long-term stockholder value; risks and uncertainties
related to our expected future revenues, operations and
expenditures; risks and uncertainties related to our, or our
current or potential partners’, ability to successfully seek and
gain approval for Qsymia in territories outside the U.S.; risks and
uncertainties related to our, or our current or potential
partners’, ability to successfully commercialize Qsymia; risks and
uncertainties related to our dialog with certain concerned member
states in Europe relating to the pending decentralized Marketing
Authorization Application, the timing and scope of the assessment
by such Concerned Member State health authorities of our Marketing
Authorization Application, and ultimately the decision of such
Concerned Member State health authorities whether to grant
Marketing Authorization for Qsymia in such EU countries; our
ability to work with the U.S. Food and Drug Administration to
significantly reduce or remove the requirements of the clinical
post-approval cardiovascular outcomes trial; and risks and
uncertainties related to our ability to sell through the Qsymia
retail pharmacy network and the Qsymia Advantage Program. These
risks and uncertainties could cause actual results to differ
materially from those referred to in these forward-looking
statements. The reader is cautioned not to rely on these
forward-looking statements. Investors should read the risk factors
set forth in VIVUS’ Form 10-K for the year ended December 31, 2018
as filed on February 26, 2019, and periodic reports filed with the
Securities and Exchange Commission. VIVUS does not undertake an
obligation to update or revise any forward-looking statements.
VIVUS, Inc. |
Investor Relations: Lazar FINN Partners |
Mark Oki |
David Carey |
Chief Financial Officer |
Senior Partner |
oki@vivus.com |
david.carey@finnpartners.com |
650-934-5200 |
212-867-1768 |
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Jun 2024 to Jul 2024
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Jul 2023 to Jul 2024